Mangoceuticals, Common Stock Stock Net Income
| MGRX Stock | 2.65 0.15 6.00% |
Mangoceuticals, Common Stock fundamentals help investors to digest information that contributes to Mangoceuticals, Common's financial success or failures. It also enables traders to predict the movement of Mangoceuticals, Stock. The fundamental analysis module provides a way to measure Mangoceuticals, Common's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mangoceuticals, Common stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -1.8 M | -1.7 M | |
| Net Loss | -9.2 M | -8.8 M | |
| Net Loss | -7.3 M | -7.7 M | |
| Net Loss | (6.45) | (6.13) |
Mangoceuticals, |
Mangoceuticals, Common Stock Company Net Income Analysis
Mangoceuticals, Common's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Mangoceuticals, Common Net Income | (9.21 M) |
Most of Mangoceuticals, Common's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mangoceuticals, Common Stock is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Mangoceuticals, Common Stock reported net income of (9.21 Million). This is 102.7% lower than that of the Health Care Equipment & Supplies sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 101.61% higher than that of the company.
Mangoceuticals, Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mangoceuticals, Common's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mangoceuticals, Common could also be used in its relative valuation, which is a method of valuing Mangoceuticals, Common by comparing valuation metrics of similar companies.Mangoceuticals, Common is currently under evaluation in net income category among its peers.
Mangoceuticals, Common ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mangoceuticals, Common's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mangoceuticals, Common's managers, analysts, and investors.Environmental | Governance | Social |
Mangoceuticals, Fundamentals
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (13.05) % | ||||
| Current Valuation | 6.78 M | ||||
| Shares Outstanding | 2.49 M | ||||
| Shares Owned By Insiders | 37.45 % | ||||
| Shares Owned By Institutions | 4.69 % | ||||
| Number Of Shares Shorted | 194.4 K | ||||
| Price To Book | 0.49 X | ||||
| Price To Sales | 7.60 X | ||||
| Revenue | 731.49 K | ||||
| Gross Profit | 4.85 K | ||||
| EBITDA | (9.19 M) | ||||
| Net Income | (9.21 M) | ||||
| Total Debt | 128.68 K | ||||
| Book Value Per Share | 0.54 X | ||||
| Cash Flow From Operations | (7 M) | ||||
| Short Ratio | 0.21 X | ||||
| Earnings Per Share | (5.70) X | ||||
| Market Capitalization | 6.59 M | ||||
| Total Asset | 1.05 M | ||||
| Retained Earnings | (11.23 M) | ||||
| Working Capital | 607.38 K | ||||
| Net Asset | 1.05 M |
About Mangoceuticals, Common Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mangoceuticals, Common Stock's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mangoceuticals, Common using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mangoceuticals, Common Stock based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Mangoceuticals, Stock Analysis
When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.